glp-1 cardiovascular outcomes trial august 2025 A decade of progress in type 2 diabetes and disease: advances in SGLT2 inhibitors and receptor agonists – a comprehensive review GLP-1 Agonists in Cardiovascular Diseases:

Nixon and her team investigate the neurobiobehavioral and psychosocial concomitants of substance use and misuse in community and clinical populations

doi: 10.1111/bph.12490 55 SamsonSLSathyanarayanaPJogiMGonzalezEVGutierrezAKrishnamurthyRet al

Always work with your healthcare provider when adjusting doses

Neuropeptide Y stimulates osteoblastic differentiation and VEGF expression of bone marrow mesenchymal stem cells related to canonical Wnt signaling activating in vitro

As more consumers become conscious of their diet and the nutritional quality of the foods they eat, they are seeking healthier versions of their favorite products for guilt-free indulgence

Tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management, is a dual GIP and GLP-1 receptor agonist that has transformed metabolic disease treatment